Article info

Download PDFPDF

Original research
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Authors

  1. Correspondence to Dr Aung Naing; anaing{at}mdanderson.org
View Full Text

Citation

Naing A, Gainor JF, Gelderblom H, et al
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Publication history

  • Accepted February 18, 2020
  • First published March 15, 2020.
Online issue publication 
March 15, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.